Ligand to Present at the BIO CEO and Investor Conference on February 13

Published on Thursday, 09 February 2012 12:49 Written by TradersHuddle Staff

SAN DIEGO-( Business Wire )-

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer of Ligand will present at the BIO CEO and Investor Conference on Monday, February 13, 2012 at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time). The conference takes place at Waldorf-Astoria in New York.

A live webcast of the presentation will be available on the Company’s website www.ligand.com. A replay of the presentation will be archived on the site for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. We believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with future revenue-generating potential. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, muscle wasting, dyslipidemia, diabetes, anemia, asthma, rheumatoid arthritis and osteoporosis. Ligand’s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Merck, Pfizer, Eli Lilly & Company, Baxter International, Bristol-Myers Squibb, Celgene, Onyx Pharmaceuticals, Lundbeck Inc., The Medicines Company, Curis, Inc. and Rib-X Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals IncorporatedErika LuibInvestor Relations(858) 550-7896@Ligand_LGNDorLHADon Markley(310) This e-mail address is being protected from spambots. You need JavaScript enabled to view it. @LHA_IR_PR